J Korean Soc Endocrinol.  1995 Mar;10(1):45-51.

Changes of Intercellular Adhesion Molecule-1 (ICAM-1) in Sera of Patients with Graves' Diease before and after Treatment with Antithyroid Drug

• Song CU
• Ahn BS
• Jeon JS
• Lee JH
• Ahn MA
• Shong MH
• Ro HK

Abstract

Intercellular Adhesion Molecule-1(ICAM-1) plays an important role in a variety of inflammatory and immune-mediated mechanisms, including lymphocyte recruitment and targeting, antigen presentation and recognition, and lymphocyte cytotoxicity.In order to study the changes of soluble ICAM-1 and relationship to the immune mechanism of Graves' disease, we performed the measurement of a soluble form of ICAM-1 in sera from patients with Graves' disease before and after treatment with antithyroid drugs using a highly sensitive ELISA method.Our results were as followed.1) The serum levels of soluble ICAM-1 in patients with Graves' disease before treatment were significantly elevated than normal controls(p<0.001).2) The serum levels of soluble ICAM-1 in patients with Graves' disease after treatment significantly decreased after treatment(p<0.001) but not as low as normal controls. 3) The serum levels of soluble ICAM-1 molecule in patients with ophthalmopathy were not elevated compared to patients with no ophthalmopathy(p>0.2).4) The serum levels of soluble ICAM-1 showed no significant correlation with serum titers of anti-thyroperoxidase antibody and anti-thyroglobulin antibody, serum T_3, T_4, TSH and goiter size in patients with Graves' disease.In conclusion, the soluble ICAM-1 levels reflect the activity of autoimmune reaction and might be used as a index of efficacy of antithyroid drug treatment of Graves' disease.

MeSH Terms

Antigen Presentation
Antithyroid Agents
Enzyme-Linked Immunosorbent Assay
Goiter
Graves Disease
Humans
Intercellular Adhesion Molecule-1*
Lymphocytes
Antithyroid Agents
Intercellular Adhesion Molecule-1